Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Experimental Chemotherapy PDF full book. Access full book title Experimental Chemotherapy by R. J. Schnitzer. Download full books in PDF and EPUB format.
Author: R. J. Schnitzer Publisher: Elsevier ISBN: 1483273083 Category : Medical Languages : en Pages : 1027
Book Description
Experimental Chemotherapy, Volume I, attempts to condense the existing knowledge in the broad field of experimental chemotherapy in a comprehensive form. The arrangement of the subject matter follows a plan by which the not always avoidable repetitive description is reduced to a minimum. In most of the protozoan and metazoan infections it appeared advantageous to discuss the different series of active compounds according to the specific diseases and their causative agents. In other cases, owing to the wide range of activity of certain antibacterials, the material is arranged according to the groups of compounds. This first volume deals with infections caused by parasites, both protozoan and metazoan; it also contains general chapters on history of chemotherapy, toxicology, statistics, and drug resistance. It is hoped that the treatise will be useful to experimental workers engaged in the search for new chemotherapeutic remedies and in the study of their mechanism of action; to all who are involved in the teaching of pharmacology and therapeutics; and to physicians and veterinarians interested in the experimental basis of the drugs they are using.
Author: R. J. Schnitzer Publisher: Elsevier ISBN: 1483273083 Category : Medical Languages : en Pages : 1027
Book Description
Experimental Chemotherapy, Volume I, attempts to condense the existing knowledge in the broad field of experimental chemotherapy in a comprehensive form. The arrangement of the subject matter follows a plan by which the not always avoidable repetitive description is reduced to a minimum. In most of the protozoan and metazoan infections it appeared advantageous to discuss the different series of active compounds according to the specific diseases and their causative agents. In other cases, owing to the wide range of activity of certain antibacterials, the material is arranged according to the groups of compounds. This first volume deals with infections caused by parasites, both protozoan and metazoan; it also contains general chapters on history of chemotherapy, toxicology, statistics, and drug resistance. It is hoped that the treatise will be useful to experimental workers engaged in the search for new chemotherapeutic remedies and in the study of their mechanism of action; to all who are involved in the teaching of pharmacology and therapeutics; and to physicians and veterinarians interested in the experimental basis of the drugs they are using.
Author: Emel Canbay Publisher: Springer ISBN: 3319129376 Category : Medical Languages : en Pages : 127
Book Description
This book has been designed to provide the full description of the comprehensive management of peritoneal surface malignancies as a new emerging specialty. Combined treatment of cytoreductive surgery (CRS) and hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) introduced by our leader Paul H. Sugarbaker are performed to treat peritoneal metastases by surgeons all around the world. Therefore this book is focused on detailed surgical anatomy of the peritoneum, preoperative clinical assessment of the peritoneal surface malignancy, patient preparation and operation room equipments, different surgical procedures for CRS and reconstruction, intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC) and neoadjuvant intraperitoneal chemotherapy, early postoperative intraperitoneal chemotherapy (EPIC) and molecular basis of peritoneal surface malignancies. The chapter on molecular mechanisms of the formation of peritoneal carcinomatosis provides insight into a rapidly expanding knowledge within this speciality. This book should be valuable for surgical oncologists who deal with multimodal treatment for peritoneal surface malignancies, as well as for the trained peritonectomy surgeons. For the senior surgeons, it will also introduce new techniques and approaches in this field such as dealing with the omental cakes and massive organ involvement that requires multi-organ resection.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 030904491X Category : Medical Languages : en Pages : 225
Book Description
Americans praise medical technology for saving lives and improving health. Yet, new technology is often cited as a key factor in skyrocketing medical costs. This volume, second in the Medical Innovation at the Crossroads series, examines how economic incentives for innovation are changing and what that means for the future of health care. Up-to-date with a wide variety of examples and case studies, this book explores how payment, patent, and regulatory policiesâ€"as well as the involvement of numerous government agenciesâ€"affect the introduction and use of new pharmaceuticals, medical devices, and surgical procedures. The volume also includes detailed comparisons of policies and patterns of technological innovation in Western Europe and Japan. This fact-filled and practical book will be of interest to economists, policymakers, health administrators, health care practitioners, and the concerned public.
Author: Institute of Medicine Publisher: National Academies Press ISBN: 0309163358 Category : Medical Languages : en Pages : 151
Book Description
An ideal health care system relies on efficiently generating timely, accurate evidence to deliver on its promise of diminishing the divide between clinical practice and research. There are growing indications, however, that the current health care system and the clinical research that guides medical decisions in the United States falls far short of this vision. The process of generating medical evidence through clinical trials in the United States is expensive and lengthy, includes a number of regulatory hurdles, and is based on a limited infrastructure. The link between clinical research and medical progress is also frequently misunderstood or unsupported by both patients and providers. The focus of clinical research changes as diseases emerge and new treatments create cures for old conditions. As diseases evolve, the ultimate goal remains to speed new and improved medical treatments to patients throughout the world. To keep pace with rapidly changing health care demands, clinical research resources need to be organized and on hand to address the numerous health care questions that continually emerge. Improving the overall capacity of the clinical research enterprise will depend on ensuring that there is an adequate infrastructure in place to support the investigators who conduct research, the patients with real diseases who volunteer to participate in experimental research, and the institutions that organize and carry out the trials. To address these issues and better understand the current state of clinical research in the United States, the Institute of Medicine's (IOM) Forum on Drug Discovery, Development, and Translation held a 2-day workshop entitled Transforming Clinical Research in the United States. The workshop, summarized in this volume, laid the foundation for a broader initiative of the Forum addressing different aspects of clinical research. Future Forum plans include further examining regulatory, administrative, and structural barriers to the effective conduct of clinical research; developing a vision for a stable, continuously funded clinical research infrastructure in the United States; and considering strategies and collaborative activities to facilitate more robust public engagement in the clinical research enterprise.
Author: National Research Council Publisher: National Academies Press ISBN: 030918651X Category : Medical Languages : en Pages : 163
Book Description
Randomized clinical trials are the primary tool for evaluating new medical interventions. Randomization provides for a fair comparison between treatment and control groups, balancing out, on average, distributions of known and unknown factors among the participants. Unfortunately, these studies often lack a substantial percentage of data. This missing data reduces the benefit provided by the randomization and introduces potential biases in the comparison of the treatment groups. Missing data can arise for a variety of reasons, including the inability or unwillingness of participants to meet appointments for evaluation. And in some studies, some or all of data collection ceases when participants discontinue study treatment. Existing guidelines for the design and conduct of clinical trials, and the analysis of the resulting data, provide only limited advice on how to handle missing data. Thus, approaches to the analysis of data with an appreciable amount of missing values tend to be ad hoc and variable. The Prevention and Treatment of Missing Data in Clinical Trials concludes that a more principled approach to design and analysis in the presence of missing data is both needed and possible. Such an approach needs to focus on two critical elements: (1) careful design and conduct to limit the amount and impact of missing data and (2) analysis that makes full use of information on all randomized participants and is based on careful attention to the assumptions about the nature of the missing data underlying estimates of treatment effects. In addition to the highest priority recommendations, the book offers more detailed recommendations on the conduct of clinical trials and techniques for analysis of trial data.
Author: Pamela M. Marcus Publisher: Springer Nature ISBN: 3030945774 Category : Biology-Research Languages : en Pages : 138
Book Description
Cancer screening is a prominent strategy in cancer control in the United States, yet the ability to correctly interpret cancer screening data eludes many researchers, clinicians, and policy makers. This open access primer rectifies that situation by teaching readers, in simple language and with straightforward examples, why and how the population-level cancer burden changes when screening is implemented, and how we assess whether that change is of benefit. This book provides an in-depth look at the many aspects of cancer screening and its assessment, including screening phenomena, performance measures, population-level outcomes, research designs, and other important and timely topics. Concise, accessible, and focused, Assessment of Cancer Screening: A Primer is best suited to those with education or experience in clinical research or public health in the United States - no previous knowledge of cancer screening assessment is necessary. This is the first text dedicated to cancer screening theory and methodology to be published in 20 years.
Author: R Schnitzer Publisher: Elsevier ISBN: 032314330X Category : Technology & Engineering Languages : en Pages : 695
Book Description
Experimental Chemotherapy, Volume IV: Chemotherapy of Neoplastic Diseases, Part I focuses on the use of chemotherapy to counteract neoplastic ailments. The book first discusses the chemotherapy of neoplastic diseases, and this includes approaches to cancer chemotherapy, methods of drug evaluation, and the effects of antitumor antibiotics. The text also presents an appendix to the previous volumes. Toxicity and drug resistance in chemotherapy; chemotherapy of trypanosomiasis, giardiasis, and histomoniasis; and the use of antibiotics in chemotherapy are discussed. Experiments on the processes, methodologies, and medical interventions on the chemotherapy of these ailments are given importance. The book also identifies some antibiotics used in the chemotherapy of fungal and bacterial infections. These antibiotics include pimaricin, fucidin, gramicidin, lincomycin, and rifamycin SV. The book is a vital reference for readers wanting to explore the potential of chemotherapy on medical interventions on neoplastic diseases.
Author: Gretchen Krueger Publisher: JHU Press ISBN: 1421429187 Category : Medical Languages : en Pages : 229
Book Description
Gretchen Krueger's poignant narrative explores how doctors, families, and the public interpreted the experience of childhood cancer from the 1930s through the 1970s. Pairing the transformation of childhood cancer from killer to curable disease with the personal experiences of young patients and their families, Krueger illuminates the twin realities of hope and suffering. In this social history, each decade follows a family whose experience touches on key themes: possible causes, means and timing of detection, the search for curative treatment, the merit of alternative treatments, the decisions to pursue or halt therapy, the side effects of treatment, death and dying—and cure. Recounting the complex and sometimes contentious interactions among the families of children with cancer, medical researchers, physicians, advocacy organizations, the media, and policy makers, Krueger reveals that personal odyssey and clinical challenge are the simultaneous realities of childhood cancer. This engaging study will be of interest to historians, medical practitioners and researchers, and people whose lives have been altered by cancer.
Author: R. J. Schnitzer
Author: R. J. Schnitzer
Author: R Schnitzer
Author: Emel Canbay
Author: Robert J. Schnitzer
Author: Institute of Medicine
Author: Institute of Medicine
Author: National Research Council
Author: Pamela M. Marcus
Author: R Schnitzer
Author: Gretchen Krueger